Recent Updates
Recently added Catalysts

SSP-004184

Phase 1

Impaired Renal Function | Small molecule | Nephrology |Takeda Pharmaceutical Company Limited|Last Updated: Jun 10, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment66
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01716455Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal FunctionPHASE1 COMPLETED 66Oct 29, 2012Mar 10, 2013Jun 10, 20212 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Area Under the Plasma Concentration-time Curve (AUC) of SSP-004184
Over 96 hours post-dose

AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

Maximum Plasma Concentration (Cmax) of SSP-004184
Over 96 hours post-dose

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
SSP-004184 (Mild Renal Impairment)EXPERIMENTALAll subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
SSP-004184 (Moderate Renal Impairment)EXPERIMENTALAll subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
SSP-004184 (Severe Renal Impairment)EXPERIMENTALAll subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
SSP-004184 (End Stage Renal Disease)EXPERIMENTALAll subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
SSP-004184 (Healthy Elderly Subjects)EXPERIMENTALAll subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
SSP-004184 (Matched Healthy Subjects)EXPERIMENTALAll subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1. Healthy subjects matched to renally impaired subjects in arms 1 through 4. (Note: One healthy subject can match more than one renally impaired subject.)
Interventions
NameTypeDescription
SSP-004184DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 85 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: Healthy subjects * Age 18-85 years inclusive at the time of consent. The elderly treatment group will be defined by an age over 65 years. It is required that at least 4 of the subjects in the elderly group will be over 75 years old. * All subjects will be "healthy" * Normal ren...

Countries:United States
Unlock Eligibility Criteria